UCERIS Drug Patent Profile

When do Uceris patents expire, and what generic alternatives are available?

Uceris is a drug marketed by Salix and is included in two NDAs. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-seven patent family members in seventeen countries.

The generic ingredient in UCERIS is budesonide. There are twenty-two drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the budesonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Uceris

A generic version of UCERIS was approved as budesonide by TEVA PHARMS on November 18^th, 2008.

Summary for UCERIS

International Patents:	27
US Patents:	5
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for UCERIS

Paragraph IV (Patent) Challenges for UCERIS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
UCERIS	Extended-release Tablets	budesonide	9 mg	203634	1	2013-03-11

US Patents and Regulatory Information for UCERIS

UCERIS is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Salix	UCERIS	budesonide	AEROSOL, FOAM;RECTAL	205613-001	Oct 7, 2014	AB	RX	Yes	No
Salix	UCERIS	budesonide	TABLET, EXTENDED RELEASE;ORAL	203634-001	Jan 14, 2013	AB	RX	Yes	Yes			Y
Salix	UCERIS	budesonide	TABLET, EXTENDED RELEASE;ORAL	203634-001	Jan 14, 2013	AB	RX	Yes	Yes			Y
Salix	UCERIS	budesonide	TABLET, EXTENDED RELEASE;ORAL	203634-001	Jan 14, 2013	AB	RX	Yes	Yes			Y
Salix	UCERIS	budesonide	TABLET, EXTENDED RELEASE;ORAL	203634-001	Jan 14, 2013	AB	RX	Yes	Yes			Y

International Patents for UCERIS

See the table below for patents covering UCERIS around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2011102311	CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITIONS
Canada	2377301
Norway	20016108
China	1355693
European Patent Office	1183014

Supplementary Protection Certificates for UCERIS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435024	301102	Netherlands		PRODUCT NAME: COMBINATIE VAN FORMOTEROL (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN), GLYCOPYRROLAAT (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN) EN BUDESONIDE (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN); REGISTRATION NO/DATE: EU/1/20/1498 20201210
2435024	202140009	Slovenia		PRODUCT NAME: COMBINATION OF FORMOTEROL (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF), GLYCOPYRROLATE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF) AND BUDESONIDE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF); NATIONAL AUTHORISATION NUMBER: EU/1/20/1498; DATE OF NATIONAL AUTHORISATION: 20201209; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2435024	LUC00208	Luxembourg		PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), DE GLYCOPYRRONIUM (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE BUDESONIDE (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1468 20201210
2435024	132021000000095	Italy		PRODUCT NAME: UNA COMBINAZIONE DI FORMOTEROLO (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI), GLICOPIRROLATO (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI) E BUDESONIDE (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI)(TRIXEO AEROSPHERE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1498, 20201210
2435024	2021C/518	Belgium		PRODUCT NAME: UNE COMBINAISON DE FORMOTEROL (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), GLYCOPYRROLATE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET BUDESONIDE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1498 20201210

Investment Scenario, Market Dynamics, and Financial Trajectory for UCERIS (Budesonide 9 mg) in Inflammatory Bowel Disease

Last updated: February 3, 2026

---

Summary

UCERIS (budesonide) is a locally acting corticosteroid designed for treating mild to moderate ulcerative colitis. As a branded therapy, it targets a specific segment in the inflammatory bowel disease (IBD) market. This analysis evaluates the current market positioning, growth prospects, competitive landscape, and financial outlook for UCERIS, considering recent launches, regulatory pathways, and evolving treatment paradigms. It concludes with core investment insights, noting that UCERIS's niche positioning and patent exclusivity influence its growth potential within the broader IBD segment.

---

What Is the Current Market Landscape for UCERIS?

Product Profile

• Active Ingredient: Budesonide 9 mg
• Indication: Mild to moderate ulcerative colitis (UC)
• Formulation: Oral, corticosteroid with high topical activity and low systemic absorption
• FDA Approval: 2013 for UC induction

Market Positioning & Differentiation

UCERIS's targeted delivery focuses on localized anti-inflammatory effects, aiming to minimize systemic corticosteroid side effects ([1]). It is positioned as an alternative to systemic corticosteroids, with advantages in safety and tolerability.

Market Size & Revenue

• Global UC Market (2022): Estimated at USD 4.1 billion, with a CAGR of approximately 5% ([2])
• UCERIS's Sales (2022): Approx. USD 300 million; growth driven by increased diagnosis and prescribing**

Year	Estimated Global UC Market (USD bn)	UCERIS Revenue (USD mn)	Market Share
2020	3.9	250	6.4%
2021	4.0	275	6.9%
2022	4.1	300	7.3%

---

Market Dynamics Influencing UCERIS

1. Competitive Landscape

• Top Competitors:
  • Mesalamine formulations (e.g., Pentasa, Asacol)
  • Oral corticosteroids (systemic)
  • Other targeted therapies (e.g., biologics like infliximab, vedolizumab)

Competitor	Type	Market Share (Estimated)	Pros	Cons
Pentasa	Aminosalicylate	~20%	Established efficacy	Less effective in moderate UC
Entocort EC	Budesonide (extraintestinal)	N/A	Similar mechanism	Different formulation, limited indication
Biologics	Monoclonal antibodies	~30%	Effective in moderate-severe UC	Cost, administration route

Source: [2], [3]

2. Regulatory & Patent Landscape

• Patent Expiry & Exclusivity: Patents for UCERIS extend until 2027, providing a window for sales growth. No generic versions are commercially available yet.
• Regulatory Approvals: FDA and EMA approvals in multiple markets; ongoing efforts for expanded indications.

3. Treatment Paradigm Shifts

• Growing preference for localized corticosteroids due to safety profile
• Increasing adoption of biologics and small molecules in moderate-to-severe cases, yet UCERIS retains a niche in induction therapy
• The pipeline includes biosimilars and newer therapies aiming at remission induction and maintenance

4. Insurance & Reimbursement Trends

• Favorable coverage for branded UCERIS in major markets
• Cost-effectiveness modeled against systemic steroids and biologics, supporting continued market adoption

---

Financial Trajectory Projections

Revenue Forecasts (2023–2030)

Year	Projected Revenue (USD mn)	Assumptions & Drivers
2023	330	Continued market penetration, stable demand
2024	360	Patent protection maintains exclusivity; slight market share increase
2025	390	Launch of expanded indications? Biosimilar competition unlikely until 2027
2026	410	Peak sales, potential slight decline due to upcoming patent expiry
2027	380	Patent expiration; generic entry expected, pressure on price
2028–2030	350–300	Market erosion, market share shift to generics/competitors

Note: These projections depend heavily on market adoption, regulatory decisions, and competitive responses.

Cost & Profitability

• R&D & Marketing: Significant investment in market education and lifecycle management
• Gross Margin: Estimated at ~80% given high-margin specialty drugs
• Net Profit Margin: Projected to decline post-2027 due to generic competition

---

Comparison with Alternate Therapy Pathways

Table: Treatment Options for Mild to Moderate UC

Therapy	Route of Administration	Onset of Action	Safety Profile	Market Share (2022)	Limitations
UCERIS	Oral	2–4 weeks	Favorable	7%	Limited to mild/moderate UC, inductive
Mesalamine	Oral, rectal	1–4 weeks	Good	~20%	Less effective in active disease
Systemic steroids	Oral, IV	1 week	Poor (long-term adverse effects)	~10%	Short-term use preferred
Biologics	IV or SC	4–8 weeks	Excellent	~30%	Cost, administration

Implication for Investment

UCERIS maintains relevance within its niche, but growth potential will depend on market penetration, differentiated positioning, and upcoming competition.

---

Deep Dive: Investment Opportunities and Risks

Opportunities

• Expanding into maintenance therapy (pending approval)
• Entry into emerging markets with increasing IBD prevalence
• Lifecycle extension through formulation innovations
• Strategic partnerships for combination therapies

Risks

• Patent expiry in 2027 leading to generic competition
• Emergence of superior or more cost-effective therapies
• Evolving treatment guidelines favoring biologics
• Pricing pressures from healthcare systems

---

Key Market Drivers & Barriers

Drivers	Barriers
Growing IBD prevalence globally	Patent expiration in 2027
Favorable safety profile	Competition from biologics and biosimilars
Increasing physician acceptance of targeted corticosteroids	Limited expansion beyond induction phase
Reimbursement policies favorable to niche drugs	Market saturation in developed countries

---

Conclusion: Investment Outlook

UCERIS's current valuation is supported by its patent exclusivity, differentiated mechanism, and targeted application in mild to moderate UC. However, revenue growth prospects are tempered by impending patent expiry and competition. Strategic investments should focus on market expansion opportunities, pipeline development (e.g., new indications), and lifecycle management initiatives.

Short-term: Maintain position, monitor sales growth, and prepare for patent expiry impacts.
Long-term: Explore licensing, partnership, or development collaborations to extend product lifecycle or diversify portfolio.

---

Key Takeaways

• UCERIS benefits from a differentiated, targeted delivery system with a niche market focus and established safety profile.
• Revenue generated (~USD 300M in 2022) is expected to grow modestly till 2026, with a peak approaching patent expiration in 2027.
• The competitive landscape is intensifying, especially with the rise of biologics and biosimilars, which could erode market share post-patent expiry.
• Market expansion and formulation line extensions present opportunities for growth; however, competitive pressure remains significant.
• Strategic planning should account for patent lifecycle, emerging treatment trends, and potential biosimilar entry.

---

FAQs

Q1: What is the primary indication for UCERIS, and are there approved broader indications?
A: UCERIS is approved for induction of remission in mild to moderate ulcerative colitis. Currently, it has no broader indications; expansion depends on regulatory approvals based on clinical trial data.

Q2: How does UCERIS differentiate itself from systemic corticosteroids?
A: UCERIS delivers budesonide locally with minimal systemic absorption, reducing adverse effects typically associated with systemic corticosteroids.

Q3: When is patent expiry anticipated, and how might this affect revenue?
A: Patent expiry is projected around 2027, after which generics are expected to enter the market, significantly eroding revenue if no lifecycle extensions occur.

Q4: How does UCERIS compare with biologics in terms of efficacy and safety?
A: UCERIS is effective for induction in mild to moderate UC with a superior safety profile and fewer systemic side effects compared to biologics, which are reserved for moderate to severe cases.

Q5: What are the main barriers to market expansion for UCERIS?
A: Limited to a niche (mild to moderate UC), impending patent expiration, and competition from emerging biologics and biosimilars are primary barriers.

---

References

[1] U.S. Food and Drug Administration. (2013). UCERIS (budesonide) Prescribing Information.

[2] Grand View Research. (2022). Inflammatory Bowel Disease Market Size, Share & Trends Analysis.

[3] IQVIA. (2022). Top Prescribed Drugs in IBD and Market Competitors.

---